A Comparative study of Rosuvastatin and Fenofibrate as Monotherapy in Dyslipidemia and NCEP ATP III Goals
Abstract
Background: Dyslipidemia is the commonest cause of the cardiovascular diseases and increases mortality worldwide. It leads to disturbance in the range of Total Cholesterol, LDL-C, VLDL and HDL-C in the plasma of dyslipidemic patients. Most of the studies relating to the effectiveness of Rosuvastatin and Fenofibrate have been conducted in the western countries and scant attention has been paid to examine the effectiveness of these drugs on the people of South Asian countries. The present study is an effort to focus on the effectiveness of these drugs on the people of Majha region of Punjab, India.
Aim:Â To see the effects of both drugs as monotherapy on the various parameters of lipid profile and goals achieved according to NCEP-ATP III guidelines in North Indian population.
Material and Methods: This was a randomized, open label, parallel study conducted to assess the effect of rosuvastatin 10 mg and fenofibrate 160 mg daily for 12 weeks in newly diagnosed dyslipidemic patients (n=60). Patients were evaluated at day 0 and at 6 and 12 weeks.
Results:
At 6 weeks there were falls for Total cholesterol by 20.41% vs. 15.64% (p< 0.001, both), triglycerides 16.21% vs. 19.85% (p< 0.001, both) and LDL-C 27.47% vs. 21.43% (p< 0.001, both) respectively with rosuvastatin and fenofibrate from baseline. And at 12 weeks plasma levels continued to fall for Total cholesterol by 35.79% vs. 25.60% (p< 0.001, both), triglycerides 29.30% vs. 39.92% (p< 0.001, both), LDL-C 47.82% vs. 34.67% (p< 0.001, both), and there was rise of HDL-C levels by 18.75% vs. 30.53% (p< 0.001, both) respectively with rosuvastatin and fenofibrate. Both the agents achieved desired goals of NCEP-ATP III for Total Cholesterol, Triglyceride, LDL, HDL and also treat the metabolic syndrome (by 39.22% and 42.66% respectively) patients.
Conclusion: Rosuvastatin and Fenofibrate monotherapy in patients with dyslipidemia effectively improved the Lipid profile as both these agents have had achieved the desired goal to treat the components of metabolic syndrome and other NCEP-ATP III targets.
Key words: Dyslipidemia, Metabolic syndrome, NCEP-ATP III goals, Fenofibrate and Rosuvastatin.
DOI
https://doi.org/10.22270/jddt.v3i4.583Published
Abstract Display: 707 
PDF Downloads: 689 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.